International Journal of Drug Delivery Technology
Volume 14, Issue 2

Polymeric Nanoparticle-Mediated Targeted Drug Delivery System: A Promising Approach for Breast Cancer

Naimish Nanda1*, Chozharajan Tharmaraj2, M Akiful Haque3, Swapna S3

1Faculty of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh, India.

2Department of Pharmaceutics, Immanuel Arasar College of Pharmacy, Nattalam, Marthandam, India.

3School of Pharmacy, Anurag University, Ghatkesar, Telangana, India.

Received: 15th January, 2024; Revised: 08th March, 2024; Accepted: 25th April, 2024; Available Online: 25th June, 2024 

ABSTRACT

After lung cancer, breast cancer (BC) is the second most frequent malignancy in women globally. Surgery followed by chemotherapy is the conventional treatment plan for BC. However, both are unsuccessful in treating BC because of the harmful effects that these treatments have on healthy tissues and organs. Many polymeric nanoparticles (PNPs) have been discovered and created recently to selectively aim cancer cells without harming normal cells. As an outcome, drug delivery systems (DDS) mediated by NPs have developed as a possible method to treat BC. PNPs have several special qualities that make them ideal for cancer treatment due to their tunable surface functions and choosiness to target tumor cells and minimize side effects

Keywords: Breast cancer, Polymeric nanoparticles, Drug delivery systems, Side effects, Tumor.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.89

How to cite this article: Nanda N, Tharmaraj C, Haque MA, Swapna S. Polymeric Nanoparticle-Mediated Targeted Drug Delivery System:APromisingApproach for Breast Cancer. International Journal of Drug Delivery Technology. 2024;14(2):1225-1231.

REFERENCES

  1. Feng T, Ai X, Ong H, Zhao Dual-Responsive Carbon Dots for Tumor Extracellular Microenvironment Triggered Targeting and Enhanced Anticancer Drug Delivery. ACS Appl Mater Interfaces. 2016;8(29):18732-40.doi: 10.1021/acsami.6b06695.
  2. Saulite L, Pleiko K, Popena I, Dapkute D, Rotomskis R, Riekstina U. Nanoparticle delivery to metastatic breast cancer cells by nanoengineered mesenchymal stem cells. Beilstein J Nanotechnol. 2018;9: 321-332. doi: 10.3762/bjnano.9.32.
  3. Cai S, Thati S, Bagby TR, Diab HM, Davies NM, Cohen MS, Forrest Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J Control Release. 2010;146(2):212-8. doi: 10.1016/j.jconrel.2010.04.006.
  4. Truffi M, Colombo M, Sorrentino L, Pandolfi L, Mazzucchelli S, Pappalardo F, Pacini C, Allevi R, Bonizzi A, Corsi F, Prosperi Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2- positive breast cancer cells. Sci Rep. 2018; 8(1):6563. doi: 10.1038/ s41598-018-24968-x.
  5. Karahaliloğlu, E. Kilicay, P. Alpaslan, B. Hazer, E. Baki Denkbas, Enhanced antitumor activity of epigallocatechin gallate–conjugated dual-drug-loaded polystyrene–polysomal– diethanol amine nanoparticles for breast cancer therapy, J. Bioact. Compat. Polym.2018; 33(3): 38–62. doi: 10.1177/0883911517710811
  6. Mao JJ, Chung A, Benton A, Hill S, Ungar L, Leonard CE, Hennessy S, Holmes Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013;22(3):256-62. doi: 10.1002/ pds.3365.
  7. Singh SK, Singh S, Lillard JW Jr, Singh R. Drug delivery approaches for breast cancer. Int J Nanomedicine. 2017;12:6205- doi: 10.2147/IJN.S140325.
  8. Jin S, Ye Targeted drug delivery for breast cancer treatment.Recent Pat Anticancer Drug Discov. 2013;8(2):143-53. doi:10.2174/1574892811308020003
  9. Tacar O, Sriamornsak P, Dass Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157-70. doi: 10.1111/j.2042-7158.2012.01567.x.
  10. Li W, Chen H, Yu M, Fang J. Targeted delivery of doxorubicin using a colorectal cancer-specific ssDNA aptamer. Anat Rec (Hoboken). 2014;297(12):2280-8. doi: 10.1002/ar.22990.
  11. Mu Q, Kievit FM, Kant RJ, Lin G, Jeon M, Zhang M. Anti- HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer Nanoscale. 2015;7(43):18010-4. doi: 10.1039/c5nr04867b.
  12. P. de Sousa Marcial, G. Carneiro, E.A. Leite, Lipid-based nanoparticles as drug delivery system for paclitaxel in breast cancer treatment, J. Nanopart. Res. 2017; 19:340-350.doi: 10.1007/ s11051-017-4042-0
  13. Li Y, Humphries B, Yang C, Wang Z. Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities. Nanomaterials (Basel). 2018; 24;8(6):361.doi: 10.3390/nano8060361.
  14. Chainitikun S, Long JP, Rodriguez-Bautista R, Iwase T, Tripathy D, Fujii T, Ueno The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Breast Cancer Res Treat. 2020 ;183(3):729-739. doi: 10.1007/s10549-020-05837-6.
  15. You Y, Xu Z, Chen Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer. Drug Deliv. 2018;25(1):448-460. doi: 10.1080/10717544.2018.1435746.
  16. Miziak P, Baran M, Błaszczak E, Przybyszewska-Podstawka A, Kałafut J, Smok-Kalwat J, Dmoszyńska-Graniczka M, Kiełbus M, Stepulak A. Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel). 2023 ; 23;15(19):4689. doi: 10.3390/
  17. Sampayo R, Recouvreux S, Simian M. The hyperplastic phenotype in PR-A and PR-B transgenic mice: lessons on the role of estrogen and progesterone receptors in the mouse mammary gland and breast cancer. Vitam Horm. 2013;93:185-201. doi: 1016/B978-0-12-416673-8.00012-5
  18. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55-62. doi: 5858/2010-0454-RAR.1.
  19. Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2015; 1;75(11):2316-2325. doi: 10.1158/0008-5472. CAN-14-3485.
  20. Hanafi-Bojd MY, Jaafari MR, Ramezanian N, Xue M, Amin M, Shahtahmassebi N, Malaekeh-Nikouei Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Eur J Pharm Biopharm. 2015;89:248-58. doi: 10.1016/j.ejpb.2014.12.009.
  21. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011 ;18;63(3):131-5. doi: 10.1016/j.addr.2010.03.011.
  22. Wong MY, Chiu Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model.Nanomedicine. 2011;7(6):834-40. doi: 10.1016/j.nano.2011.02.001.
  23. Yoo J, Park C, Yi G, Lee D, Koo Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. Cancers (Basel). 2019; 8;11(5):640. doi: 10.3390/ cancers11050640.
  24. Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors. Front Pharmacol. 2021; 3;12:601626. doi: 10.3389/fphar.2021.601626.
  25. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2011;3(3):1377-1397. doi: 3390/polym3031377.
  26. Cheng, F. Meng, C. Deng, H.-A. Klok, Z. Zhong, Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery, Biomaterials. 2013; 34:3647–3657. doi: 10.1016/j.biomaterials.2013.01.084.
  27. Rao, P. and Geckeler, K.E. Polymer Nanoparticles: Preparation Techniques and Size-Control Parameters. Progress in Polymer Science, 2011;36, 887-913. doi: 10.1016/j.progpolymsci.2011.01.001
  28. Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C Mater Biol Appl. 2016; 60:569-578. oi: 1016/j.msec.2015.11.067.
  29. Shenoy DB, Amiji MM. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm. 2005;293(1-2):261-70. doi: 10.1016/j.ijpharm.2004.12.010.
  30. Pandey SK, Patel DK, Maurya AK, Thakur R, Mishra DP, Vinayak M, Haldar C, Maiti P. Controlled release of drug and better bioavailability using poly(lactic acid-co-glycolic acid) Int J Biol Macromol. 2016;89:99-110. doi: 10.1016/j. ijbiomac.2016.04.065.
  31. Jin, J. Pi, Y. Zhao, J. Jiang, T. Li, X. Zeng, P. Yang, C.E. Evans, J. Cai, EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy, Nanoscale. 2017;9:16365–16374. doi: 10.1039/C7NR06898K
  32. Wong KH, Lu A, Chen X, Yang Z. Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment. Molecules. 2020;25(16):3620. doi: 10.3390/molecules25163620.
  33. Yousefi Rizi HA, Hoon Shin D, Yousefi Rizi S. Polymeric Nanoparticles in Cancer Chemotherapy: A Narrative Review. Iran J Public Health. 2022;51(2):226-239. doi: 10.18502/ijph. 8677.
  34. Ding L, Agrawal P, Singh SK, Chhonker YS, Sun J, Murry DJ. Polymer-Based Drug Delivery Systems for Cancer Polymers. 2024; 16(6):843. doi: 10.3390/polym16060843.
  35. Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv. 2012;2012:915375. doi: 1155/2012/915375.
  36. Kumari, S.K. Yadav, S.C. Yadav, Biodegradable polymeric nanoparticles based drug delivery systems, Colloids Surf. B. 2010;75: 1–18. doi: 10.1016/j.colsurf b.2009.09.001.
  37. Jin G, He R, Liu Q, Dong Y, Lin M, Li W, Xu F. Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles. ACS Appl Mater 2018;10(13):10634- 10646. doi: 10.1021/acsami.7b14603.
  38. Jayakumar, M. Prabaharan, S. Nair, H. Tamura, Novel chitin and chitosan nanofibers in biomedical applications, Biotechnol. Adv.2010;28: 142–150. doi: 10.1016/j.biotechadv.2009.11.001.
  39. Gao C., Tang F., Zhang J., Lee S.M.Y., Wang R. Glutathione- responsive nanoparticles based on a sodium alginate derivative for selective release of doxorubicin in tumor J. Mater. Chem.B. 2017;5:2337–2346. doi: 10.1039/C6TB03032G
  40. Raghav, ; Vashisth, C.; Mor, N.; Arya, P.; Sharma, M.R.; Kaur, R.; Bhatti, S.P.; Kennedy, J.F. Recent advances in cellulose, pectin, carrageenan and alginate-based oral drug delivery systems. Int. J. Biol. Macromol. 2023, 244, 125357. doi: 10.1016/j. ijbiomac.2023.125357.
  41. Ulbrich , Hola K., Subr V., Bakandritsos A., Tucek J., Zboril R. Targeted drug delivery with polymers and magnetic nanoparticles: Covalent and noncovalent approaches, release control, and clinical studies. Chem. Rev. 2016;116:5338–5431. doi: 10.1021/acs.chemrev.5b00589.
  42. Nam NH, Luong Nanoparticles: synthesis and applications. Materials for Biomedical Engineering. 2019:211–40. doi: 10.1016/ B978-0-08-102814-8.00008-1.
  43. Hoa LTM, Chi NT, Nguyen LH, Chien DM. Preparation and characterisation of nanoparticles containing ketoprofen and acrylic polymers prepared by emulsion solvent evaporation method. J Exp 2012;7(2):189–97. doi: 10.1080/17458080.2010.515247
  44. Yadav KS, Sawant KK. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS 2010 ;11(3):1456-65. doi: 10.1208/s12249-010-9519-4.
  45. Franco P, De Marco I. Supercritical Antisolvent Process for Pharmaceutical Applications: A Review. Processes. 2020; 8(8):938. doi: 10.3390/pr8080938